Sign in to view content

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO

Nikhil K Bommakanti, MD

Video
Published 2024

Related

Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Prospective Trial Comparing Ranibizumab Monthly to Treat and Extent With and Without Angiography-Guided Laser for DME
John F. Payne, MD
Updates from the Field
2016
Effect of 6 month anti-VEGF treatment for proliferative diabetic retinopathy on the quantitative metrics of the retinal microvasculature on OCTA
Quan V. Hoang, MD, PhD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more